• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic Analysis of Immuno-gene Therapy for Melanoma Using Functional Characteristic of CD82

Research Project

Project/Area Number 09670905
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Dermatology
Research InstitutionYAMANASHI MEDICAL UNIVERSITY

Principal Investigator

SHIBAGAKI Naotaka  Yamanashi Medical University, School of Medicine, Assistant staff., 医学部, 助手 (40262662)

Co-Investigator(Kenkyū-buntansha) HAMADA Hirofumi  Japanese Cancer Institute, Cancer Chemotherapy Center, Chief., 部長 (00189614)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 1998: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1997: ¥1,600,000 (Direct Cost: ¥1,600,000)
KeywordsCD82 / MELANOMA / CELL ADHESION / CANCER VACCINATION
Research Abstract

To define T-cell costimulatory molecules that work in the early phase of T-cell activation, we established monoclonal antibodies (mAbs) that inhibit or enhance T-cell activation by histiocytic leukemia cell line U937. One of the mAbs, 53H5, that recognized both T cells and U937 was identified to bind to CD82 by expression cloning. Functional analyses of CD82 revealed the following : 1) CD82 needs to exist on both T cells and U937 for the full activation of T cells ; 2) CD82 expression is up-regulated on both T cells and U937 by stimulation such as CD3 ligation or PMA treatment ; 3) overexpression of CD82 enhances both homotypic and heterotypic cell adhesion between T cells and U937 ; 4) CD82 signal costimulates T cells and the signal works synergistically with the CD28-mediated T-cell costimulation signal ; 5) in mixed leukocyte reaction (MLR) using U937 as stimulator cells, CD82 overexpression on U937 correlates with the higher allogeneicity of U937 cells ; 6) overexpression of CD82 on melanoma cells enhances heterotypic cell adhesion between melanoma cells and T cells. These results indicate that CD82, expressed on both T cells and antigen presenting cells or target cells, plays an important role not only as a costimulatory molecules in T cells, but also as a cell adhesion molecules.

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (3 results)

All Other

All Publications (3 results)

  • [Publications] Naotaka Shibagaki, et al.: "Functional analysis of CD82 in the early phase of T cell activation : roles in cell adhesion and signal transduction." European Journal of Immunology.28. 1125-1133 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Naotaka Shibagaki, et al.: "Functional analysis of CD82 in the early phase of T cell activation roles in cell adhesion and signal transduction." European Journal of Immunology.28. 1125-1133 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Naotaka Shibagaki, et al.: "Functional analysis of CD82 in the early phase of T cell activation:roles in cell adhesion and signal transduction." European Journal of Immunology.28. 1125-1133 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi